Old Web
English
Sign In
Acemap
>
authorDetail
>
Timothy Chiu
Timothy Chiu
Kaiser Permanente
Medicine
Physical therapy
Internal medicine
Immune system
Adverse effect
4
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Evaluation of the safety and effectiveness of switching from standard to extended interval dosing for durvalumab in unresectable stage III non-small cell lung cancer.
2021
Journal of Clinical Oncology
Stephanie Mac
Rita L. Hui
Kris Nishimura
Evelyn Tan
Timothy Chiu
Diana D. Shen
Show All
Source
Cite
Save
Citations (0)
Use of immune checkpoint inhibitors in a community practice within a vertically integrated health care system.
2018
Journal of Clinical Oncology
Robert Michael Cooper
Christopher Yamamoto
Thach-Giao Truong
Fang Niu
Helen Moon
Michele M. Spence
Jim Chan
Timothy Chiu
Rita L. Hui
Show All
Source
Cite
Save
Citations (0)
Immune-related adverse events (IrAE) of elderly patients (pts) receiving PD-1 or PDL-1 inhibitors (PDIs) in a community-oncology setting: The experience at Kaiser Permanente California.
2018
Journal of Clinical Oncology
Thach-Giao Truong
Christopher Yamamoto
Timothy Chiu
Fang Niu
Michele M. Spence
Jim Chan
Robert Michael Cooper
Helen Moon
Rita L. Hui
Show All
Source
Cite
Save
Citations (2)
Immune-related adverse events (IRAE) of elderly patients (PTS) with advanced melanoma (AMEL) treated with checkpoint inhibitors (CI) in a community setting: The experience (EXP) at Kaiser Permanente (KP) California.
2018
Journal of Clinical Oncology
Thach-Giao Truong
Helen Moon
Timothy Chiu
Christopher Yamamoto
Michele M. Spence
Juraj Kavecansky
Fang Niu
Rita L. Hui
Show All
Source
Cite
Save
Citations (0)
1